Monographie - Morphine tartrate - Stabilis 4.0

Son güncelleme :
19/11/2024

Analjezik

Morphine tartrate

Enjeksiyon

Çözeltilerin stabilitesi

Karışımlardaki stabilitesi

Stabiliteyi etkileyen faktörler

Uyumluluk

Uygulama yöntemi

Kaynaklar

pdf

Kimyasal yapı

Ticari isim

Ticari isim

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Morphine tartrate

Avustralya

Kaynaklar

Enjeksiyon

Kaynaklar : Morphine tartrate

	tip	yayın
519	Dergi	Poggi GL. Compatibility of morphine tartrate admixtures in polypropylene syringes. Aust J Hosp Pharm 1991 ; 21: 316.
920	Dergi	Targett PL, Keefe PA, Merridew CG. Stability of two concentrations of morphine tartrate in 10 mL polypropylene syringes. Aust J Hosp Pharm 1997 ; 27: 452-454.
980	Dergi	Ambados F. Compatibility of morphine and ketamine for subcutaneous infusion. Aust J Hosp Pharm 1995 ; 25: 352.
1864	Dergi	Lau MH, Hackman C, Morgan DJ. Compatibility of ketamine and morphin injections. Pain 1998 ; 75: 389-390.
2083	Dergi	La Forgia SP, Sharley NA, Burgess NG, Doecke CJ. Stability and compatibility of morphine, midazolam and bupivacaine combinaisons for iontravenous infusion. J Pharm Pract and Res 2002 ; 32: 65-68.
3474	Laboratuar	Fluorouracil - Summary of Product Characteristics Accord Healthcare Limited 2009
3504	Laboratuar	Parecoxib (Dynastat®) - Summary of Product Characteristics Pfizer 2012
3644	Laboratuar	Calcium gluconate® - Summary of Product Characteristics Hameln Pharmaceuticals 2010
3675	Laboratuar	Thiopental sodium - Summary of Product Characteristics Archimedes Pharma UK Ltd 2015
3838	Laboratuar	Magnesium Sulphate - Summary of Product Characteristics Martindale Pharmaceuticals Ltd 2007
3934	Laboratuar	Eptifibatide (Integrilin®) - Résumé des caractéristiques du produit GlaxoSmithKline Laboratoire 2016

Mentions Légales